Taking hormone replacement therapy (HRT) for at least 6 months after total knee arthroplasty (TKA) or total hip arthroplasty (THA) may reduce risk of repeat surgery. So say the results of a community-based cohort study of women in the UK who had undergone TKA or THA for osteoarthritis.
Taking hormone replacement therapy (HRT) for at least 6 months after total knee arthroplasty (TKA) or total hip arthroplasty (THA) may reduce risk of repeat surgery. So say the results of a community-based cohort study of women in the UK who had undergone TKA or THA for osteoarthritis.
Published in Annals of the Rheumatic Diseases, the population-based study looked at outcomes in 10,800 women aged ≥40 who had undergone TKA or THA between 1986 and 2006. None of the participants had a history of previous hip fracture or rheumatoid arthritis; 2,700 had taken HRT for ≥6 months whereas 8,100 had not.
At median observation of 3.3 years after TKA/THA, researchers from the University of Oxford reported a hazard ratio (HR) for need for repeat surgery of 0.62 (95% CI 0.41 to 0.94) in those who had taken HRT for ≥6 months versus 0.48 (0.29 to 0.78) in those who had taken it for ≥12 months. Rates of revision were even lower the longer a woman took HRT and the better she adhered to it. Taking HRT before surgery, however, did not influence implant survival.
The findings, which the authors say show a link between HRT use and an almost 40% reduction in revision rates after TKA/THA, require replication in external cohorts and experimental studies.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Diabetes linked to altered long-term inflammatory response in mesh implantation
July 15th 2024A recent study highlights the association between diabetes and complications from urogynecologic mesh implants, emphasizing the need for further research on glycemic control in affected patients.
Read More